ImmunityBio (IBRX) director trades 175,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

ImmunityBio director Barry J. Simon reported a mix of stock sales and equity awards for ImmunityBio, Inc. common stock. He sold 165,000 shares on February 23, 2026 in open-market transactions at a weighted average price of $10.2491 per share under a Rule 10b5-1 trading plan, and sold another 10,000 shares on February 20, 2026 at $9.25 per share. On February 22, 2026, restricted stock units representing 15,243 shares vested and were converted into common stock at no cost, with 6,026 shares withheld at $8.70 per share to cover taxes. After these transactions, he directly owned 2,925,821 shares of ImmunityBio common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simon Barry J.

(Last) (First) (Middle)

C/O IMMUNITYBIO, INC.

3530 JOHN HOPKINS COURT

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ImmunityBio, Inc. [ IBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		S(1)		10,000	D	$9.25	3,081,604	D
Common Stock(2)	02/22/2026		M		15,243	A	$0	3,096,847	D
Common Stock	02/22/2026		F		6,026	D	$8.7(3)	3,090,821	D
Common Stock	02/23/2026		S(1)		165,000	D	$10.2491(4)	2,925,821	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	02/22/2026		M			15,243	(5)	(5)	Common Stock	15,243	$0	15,245	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

3. On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld.

4. Represents the weighted average share price of an aggregate total of 165,000 shares sold in the price range of $9.89 to $10.635 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

5. Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

Remarks:

	/s/ Philip LoScalzo, as Attorney-in-Fact	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ImmunityBio (IBRX) director Barry J. Simon report?

Barry J. Simon reported open-market sales of ImmunityBio common stock plus activity related to restricted stock units. He sold 175,000 shares in total and had 15,243 RSUs vest and convert into common shares, with some shares withheld to satisfy tax obligations.

How many ImmunityBio (IBRX) shares did Barry J. Simon sell and at what prices?

Barry J. Simon sold 165,000 ImmunityBio common shares at a weighted average price of $10.2491 and 10,000 shares at $9.25. The 165,000-share sale occurred within a $9.89 to $10.635 range, as disclosed in a detailed weighted-average price footnote.

Was Barry J. Simon’s ImmunityBio (IBRX) stock sale under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan adopted on September 4, 2024. Such plans pre-schedule trades, allowing insiders to systematically sell shares over time according to prearranged instructions.

What happened to Barry J. Simon’s restricted stock units in ImmunityBio (IBRX)?

On February 22, 2026, 15,243 ImmunityBio restricted stock units vested, each converting into one common share at no purchase price. A portion of the resulting shares, 6,026, was withheld at $8.70 per share to cover tax liabilities associated with the vesting.

How many ImmunityBio (IBRX) shares does Barry J. Simon own after these transactions?

After the reported sales, RSU vesting, and related tax withholding, Barry J. Simon directly owned 2,925,821 shares of ImmunityBio common stock. This figure reflects his updated direct ownership following all transactions reported in the Form 4.

How do Barry J. Simon’s ImmunityBio (IBRX) RSUs vest over time?

The RSU award vests over three years, assuming he remains a service provider. 33.33% of the units vest on each of the first and second anniversaries of February 22, 2024, and 33.34% vest on the third anniversary, completing full vesting by year three.